Mumbai: Pharma major Lupin Limited (Lupin) announced the successful facility review carried out by Health Canada for its Pithampur Unit 2 (Indore) manufacturing facility. Following the review, Health Canada has maintained the compliant rating for Unit 2 at Pithampur (Indore) and has issued a revised ‘Establishment License’.

Commenting on the development, Nilesh Gupta, Managing Director, Lupin said: “Lupin is committed to maintaining truly global quality standards at our manufacturing units. The successful review by Health Canada is a significant milestone in that journey for Pithampur Unit 2 (Indore).”

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Paediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 11^th and 7^th largest generics pharmaceutical company by market capitalization (December 31^st, 2017, Bloomberg) and revenues (September 30^th, 2017, Bloomberg LTM) respectively. The Company is the 4^th largest pharmaceutical player in the US by prescriptions (IQVIA MAT December 2017); 2^nd largest Indian pharmaceutical company by global revenues (September 30^th, 2017, Bloomberg LTM); 6^th largest generic pharmaceutical player in Japan and 5^th largest company in Indian Pharmaceutical Market (IQVIA MAT December 2017).

For the financial year ended 31^st March, 2017, Lupin’s consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3^rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Or

Arvind Bothra
Head – Investor Relations
Email: arvindbothra@lupin.com
Ph: +91-22-66402137

*Safe Harbor Statement